| Name | Title | Contact Details |
|---|
"Enzo Life Sciences is a wholly owned subsidiary of Enzo Biochem headquartered in Farmingdale, New York. Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of healthcare both today and into the future. Underpinning Enzo Biochem’s technologies, platforms and products is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies. Enzo Life Sciences is a pioneer in labeling and detection technologies from DNA to whole cell across research and diagnostic markets. We are focused on providing cost-effective, relevant and reliable solutions for life science research, drug development, and clinical research. We are organized to lead in the development, production, marketing, and sales of innovative research tools worldwide based on 40 years’ experience in building strong global market recognition and implementing outstanding operational capabilities. Our strong portfolio of proteins, antibodies, peptides, small molecules, labeling probes, dyes and kits provides researchers tools for target identification/validation, high content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis."
Marlon Ramos at Frange Blue-Hairstylist is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Progenika is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Liberty BioSecurity’s multi-disciplinary research teams transform life science discoveries into global-class, industry leading solutions.
Corvidia Therapeutics is a biotechnology company pioneering the next generation of cardiovascular therapies. Leveraging functional genomics, the company`s founding team has decoded previously unrecognized genetic susceptibilities within general cardiovascular populations. Corvidia`s pipeline programs precisely identify patients with unique sensitivity to specific biologic pathways, potentially allowing for the rapid development of therapies targeting those pathways. This approach confers unique concepts within the field of cardiovascular medicines and an unprecedented accelerated path-to-market. Corvidia brings together a team of distinguished scientists, experienced drug developers as the management team, and a successful group of investors. Corvidia is headquartered in the Greater Boston area.